Rilvegostomig clears ctDNA and delays recurrence in high-risk head and neck cancer

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

The potential of T-cell engagers in SCLC treatment

Call for nominations: McVie-Veronesi Award - Improving cancer outcomes in LMICs

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC